查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1953543

慢性阻塞性肺病治療市場－全球產業規模、佔有率、趨勢、機會、預測：依藥物類別、類型、通路、地區和競爭格局分類，2021-2031年

Chronic Obstructive Pulmonary Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Type, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球慢性阻塞性肺病(COPD) 治療市場預計將從 2025 年的 194.2 億美元成長到 2031 年的 290.1 億美元，複合年成長率為 6.92%。

該市場專注於治療以氣流阻塞為特徵的進行性肺部疾病（尤其是肺氣腫和慢性支氣管炎）的藥品和治療設備。推動這一市場成長的關鍵因素包括全球人口老化以及吸煙和長期暴露於環境污染物等風險因素的增加。日益加重的疾病負擔導致對有效支氣管擴張劑和抗發炎療法的需求持續成長，這些藥物對於症狀控制至關重要。根據美國肺臟協會 (ALA) 估計，到 2024 年，慢性阻塞性肺病導致的年度醫療保健費用將達到 240 億美元。

市場概覽
預測期 2027-2031
市場規模：2025年 194.2億美元
市場規模：2031年 290.1億美元
複合年成長率：2026-2031年 6.92%
成長最快的細分市場 聯合治療
最大的市場 北美洲

儘管市場需求仍然強勁，但該領域面臨著許多挑戰，尤其是先進聯合治療和生物製藥的高成本。這些經濟障礙限制了患者獲得最佳治療的機會，尤其是在醫療報銷體系往往不完善的中低收入地區。因此，價格承受能力的限制可能會阻礙新治療方法的推廣應用，並抑制價格敏感地區整體市場的成長。

市場促進因素

生物製藥和標靶三聯聯合治療的引入，對於儘管接受標準治療但症狀仍無法控制的患者而言，標誌著市場的重大轉折點。製藥公司正優先研究2型發炎和新的作用機制，以降低急性惡化率並改善肺功能。例如，度普利尤單抗等生物製藥的核准，為特定疾病建立了新的治療模式，而磷酸二酯酶抑制劑則具有非類固醇抗發炎作用。根據賽諾菲2024年9月發布的關於度普利尤單抗在美國核准的新聞稿，在兩項主要的III期臨床試驗中，該生物製藥分別使中度和重度急性COPD急性加重率降低了30%和34%。這些創新進展使醫療服務提供者能夠有效地客製化治療方案，並加速在先進的醫療保健系統中引入更先進的治療選擇。

同時，空氣品質惡化和環境污染加劇正顯著加重全球疾病負擔，從而催生了對呼吸系統疾病管理解決方案的強勁需求。都市化和氣候變遷導致顆粒物和臭氧濃度上升，直接導致肺功能下降和急性呼吸道症狀的發生。根據美國肺臟協會於2024年4月發布的《2024年空氣污染狀況報告》，美國約有1.31億人居住在空氣污染水平不健康的地區，這代表著龐大的易感人群。這場環境危機凸顯了全球預防和維持治療的迫切性。為了應對這項公共衛生挑戰的嚴峻性，瑞思邁公司（ResMed Inc.）估計，到2024年，全球將有約4.8億人患有慢性阻塞性肺病（COPD），這意味著需要持續治療性介入的人數量龐大。

市場挑戰

先進聯合治療和生物製藥的高昂成本是全球慢性阻塞性肺病（COPD）治療市場的主要阻礙因素。儘管這些新治療方法能帶來卓越的臨床療效，但其高昂的價格限制了公共健保體係不完善地區的病患獲得治療的機會。這種價格差異為中低收入經濟體的患者設定了進入門檻，實際上縮小了製藥公司的潛在市場規模。當患者無法獲得最佳治療時，他們往往會減少用藥量或選擇價格較低但療效較差的替代藥物，這直接限制了高利潤專利藥物的銷售量。

此外，日益沉重的經濟負擔阻礙了創新治療方法的普及，從而抑制了整體市場擴張。患者面臨的經濟壓力是可以量化的，並且對治療的持續性有重大影響。根據澳洲肺臟基金會2024年的調查，78%的受訪者表示，他們在醫療保健和治療方面的自付費用增加。這種經濟負擔迫使患者在醫療保健和其他基本需求之間做出選擇，導致處方箋發放率下降。因此，儘管疾病盛行率不斷上升，但由於難以滲透到價格敏感型市場，製造商的收入成長速度正在放緩。

市場趨勢

智慧吸入器與數位健康監測平台的融合，正透過建構一個用於即時疾病管理的互聯生態系統，從根本上重塑市場格局。與傳統的獨立設備不同，這些數位化解決方案能夠收集關於用藥依從性和吸氣流量的客觀數據，並與醫療服務提供者的儀錶板同步，從而預測和預防症狀加重。這種互聯互通使得及時的臨床干預成為可能，有效彌合了日常自我管理與專業醫療監測之間的差距。主要產業參與者的強勁財務表現也印證了這種對互聯醫療技術的日益依賴。根據瑞思邁公司（ResMed Inc.）於2024年8月發布的「2024年第四季亮點」新聞稿，該公司軟體即服務（SaaS）營收成長了10%，這主要得益於其院外慢性病管理軟體平台的日益普及。

同時，家庭無創通氣（NIV）解決方案的日益普及標誌著呼吸照護領域向去中心化方向的重大結構性轉變。隨著醫療系統尋求減輕醫院基礎設施的負擔，病情穩定的慢性阻塞性肺病（COPD）患者從急性護理機構轉移到配備先進生命維持技術的家庭環境的趨勢正在加速發展。設備便攜性的提升和方便用戶使用介面的改進推動了這一趨勢，使普通看護者和患者都能輕鬆獲得複雜的呼吸支援。這些居家照護解決方案的市場成長動能是可以量化的。根據費雪派克醫療保健公司（Fisher & Paykel Healthcare）2024年5月發布的全年財務業績報告，居家照護產品系列的收入達到6.523億紐西蘭元，比上一會計年度成長了18%。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球慢性阻塞性肺病（COPD）治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 藥物分類（聯合治療、支氣管擴張劑、皮質類固醇、磷酸二酯酶 4 抑制劑、祛痰藥、其他）
    • 依類型（慢性支氣管炎、肺氣腫）
    • 分銷通路（醫院藥局、零售藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美慢性阻塞性肺病（COPD）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲慢性阻塞性肺病（COPD）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區慢性阻塞性肺病（COPD）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲慢性阻塞性肺病（COPD）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲慢性阻塞性肺病（COPD）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球慢性阻塞性肺病（COPD）治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Merck & Co., Inc.
  • GlaxoSmithKline plc（GSK）
  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • Novartis AG
  • Teva Pharmaceuticals Industries Ltd.
  • Pfizer Inc.
  • Mylan NV
  • Chiesi Farmaceutici SpA
  • F. Hoffmann-La Roche AG

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23958

The Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is projected to expand from USD 19.42 Billion in 2025 to USD 29.01 Billion by 2031, reflecting a compound annual growth rate of 6.92%. This market encompasses pharmaceuticals and therapeutic devices intended to manage progressive lung conditions defined by airflow obstruction, specifically emphysema and chronic bronchitis. The primary catalysts for this growth include the globally aging population and the increasing prevalence of risk factors such as tobacco use and prolonged exposure to environmental pollutants. This rising disease burden generates a sustained demand for effective bronchodilators and anti-inflammatory therapies essential for symptom management. According to the American Lung Association, the annual medical cost attributed to chronic obstructive pulmonary disease was estimated at 24 billion dollars in 2024.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 19.42 Billion
Market Size 2031USD 29.01 Billion
CAGR 2026-20316.92%
Fastest Growing SegmentCombination Therapy
Largest MarketNorth America

Despite strong demand, the sector faces significant hurdles regarding the high costs associated with advanced combination therapies and biologic drugs. This financial barrier limits patient access to optimal care, particularly in low- and middle-income regions where healthcare reimbursement frameworks are often inadequate. Consequently, affordability constraints threaten to impede the widespread adoption of newer treatment modalities and restrict overall market expansion in price-sensitive territories.

Market Driver

The introduction of biologics and targeted triple combination therapies marks a significant shift in the market, catering to patients with uncontrolled symptoms despite standard care. Pharmaceutical companies are prioritizing type 2 inflammation and novel mechanisms of action to decrease exacerbation rates and enhance lung function. For example, regulatory approvals for biologics such as dupilumab have established new treatment paradigms for specific phenotypes, while phosphodiesterase inhibitors provide non-steroidal anti-inflammatory benefits. According to a September 2024 press release from Sanofi regarding Dupixent's approval in the US, the biologic demonstrated a reduction in moderate or severe acute COPD exacerbations by 30% and 34% in two pivotal Phase 3 trials. This surge in innovation enables healthcare providers to customize regimens effectively, driving the adoption of advanced therapeutic options within developed healthcare systems.

Concurrently, deteriorating air quality and environmental pollution levels are significantly amplifying the global disease burden, creating a robust demand for respiratory management solutions. Increasing urbanization and climate change contribute to higher concentrations of particulate matter and ozone, which directly precipitate lung function decline and acute respiratory episodes. According to the American Lung Association's 'State of the Air 2024' report released in April 2024, approximately 131 million individuals in the United States reside in areas with unhealthy air pollution levels, resulting in a vast pool of susceptible patients. This environmental crisis underscores the urgent need for preventative and maintenance therapies globally. Reflecting the scale of this public health challenge, ResMed Inc. estimated in 2024 that approximately 480 million people worldwide suffer from COPD, highlighting the massive potential patient base requiring continuous therapeutic intervention.

Market Challenge

The substantial costs linked to advanced combination therapies and biologic drugs act as a primary restraint on the Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market. Although these newer treatments offer superior clinical outcomes, their premium pricing restricts access in regions where public reimbursement frameworks are insufficient. This price disparity creates a significant barrier to entry for patients in low- and middle-income economies, effectively shrinking the addressable market size for pharmaceutical companies. When patients cannot afford optimal care, they often resort to rationing medication or utilizing cheaper, less effective alternatives, which directly limits the sales volume of high-margin proprietary drugs.

Furthermore, this affordability crisis hampers overall market expansion by stifling the adoption rates of innovative modalities. The economic pressure on patients is quantifiable and significantly affects treatment adherence. According to the Lung Foundation Australia in 2024, 78 percent of survey respondents reported an increase in out-of-pocket costs for their healthcare and treatments. Such financial toxicity forces a trade-off between health management and other essential needs, leading to lower prescription fulfillment. Consequently, manufacturers face slower revenue growth as the market struggles to penetrate price-sensitive demographics despite the rising prevalence of the disease.

Market Trends

The integration of smart inhalers with digital health monitoring platforms is fundamentally reshaping the market by establishing a connected ecosystem for real-time disease management. Unlike traditional stand-alone devices, these digital solutions capture objective data on medication adherence and inspiratory flow, which is then synchronized with provider dashboards to predict and prevent exacerbations. This connectivity facilitates timely clinical interventions, effectively bridging the gap between daily self-management and professional medical oversight. This growing reliance on connected care technologies is evidenced by the robust financial performance of key industry players. According to ResMed Inc.'s 'Fourth Quarter 2024 Highlights' press release in August 2024, revenue from their Software as a Service (SaaS) business increased by 10 percent, driven by the expanding adoption of out-of-hospital software platforms that support the management of chronic conditions.

Simultaneously, the rising utilization of home-based non-invasive ventilation (NIV) solutions represents a critical structural shift toward decentralizing respiratory care. As healthcare systems strive to alleviate the burden on hospital infrastructure, there is an accelerated transition of stable COPD patients from acute care settings to home environments equipped with advanced life-support technologies. This trend is supported by improvements in device portability and user-friendly interfaces, which make complex respiratory support feasible for lay caregivers and patients. The market momentum for these home-care solutions is quantifiable; according to Fisher & Paykel Healthcare's 'FY24 Full Year Update' in May 2024, revenue for the Homecare product group reached 652.3 million New Zealand dollars, marking an 18 percent increase compared to the previous financial year.

Key Market Players

  • Merck & Co., Inc.
  • GlaxoSmithKline plc (GSK)
  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • Novartis AG
  • Teva Pharmaceuticals Industries Ltd.
  • Pfizer Inc.
  • Mylan N.V.
  • Chiesi Farmaceutici S.p.A.
  • F. Hoffmann-La Roche AG

Report Scope

In this report, the Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class

  • Combination Therapy
  • Bronchodilators
  • Corticosteroids
  • Phosphodiesterase Type 4 Inhibitor
  • Mucokinetics
  • Others

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Type

  • Chronic Bronchitis
  • Emphysema

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market.

Available Customizations:

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics, Others)
    • 5.2.2. By Type (Chronic Bronchitis, Emphysema)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Type
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By Distribution Channel

7. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Type
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Type
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Type
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By Distribution Channel

10. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Type
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Merck & Co., Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. GlaxoSmithKline plc (GSK)
  • 15.3. AstraZeneca plc
  • 15.4. Boehringer Ingelheim International GmbH
  • 15.5. Novartis AG
  • 15.6. Teva Pharmaceuticals Industries Ltd.
  • 15.7. Pfizer Inc.
  • 15.8. Mylan N.V.
  • 15.9. Chiesi Farmaceutici S.p.A.
  • 15.10. F. Hoffmann-La Roche AG

16. Strategic Recommendations

17. About Us & Disclaimer